` ADIL (Adial Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

ADIL
vs
S&P 500

Over the past 12 months, ADIL has underperformed S&P 500, delivering a return of -79% compared to the S&P 500's 9% growth.

Stocks Performance
ADIL vs S&P 500

Loading
ADIL
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
ADIL vs S&P 500

Loading
ADIL
S&P 500
Difference
www.alphaspread.com

Performance By Year
ADIL vs S&P 500

Loading
ADIL
S&P 500
Add Stock

Competitors Performance
Adial Pharmaceuticals Inc vs Peers

S&P 500
ADIL
LLY
JNJ
NOVO B
ROG
Add Stock

Adial Pharmaceuticals Inc
Glance View

Market Cap
1.9m USD
Industry
Pharmaceuticals

Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. The company is headquartered in Charlottesville, Virginia and currently employs 16 full-time employees. The company went IPO on 2018-07-27. The firm is focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) AD04 is investigated in the Company’s ONWARD pivotal Phase III clinical trial for the treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test. AD04 is used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The firm is also developing adenosine analogs for the treatment of pain and other disorders through its wholly owned subsidiary, Purnovate, Inc.

ADIL Intrinsic Value
0.403 USD
Undervaluation 41%
Intrinsic Value
Price
Back to Top